Estimation of the MCID for Patients With Knee Osteoarthritis

Sponsor
Istanbul University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06034665
Collaborator
(none)
100
1
1
21.9
4.6

Study Details

Study Description

Brief Summary

Background: The effect of exercise on knee osteoarthritis (OA) is often evaluated with patient-reported scales. The Minimal Clinically Important Difference (MCID) values of these scales are needed to understand the change in patients after treatment and to manage the treatment.

It is also one of the most important data in calculating the MCID sample size. Aim: In the literature, MCID studies for exercise applied to knee OA are limited especially for those who did not undergo surgery. Thus new studies are needed.

Method: 100 patients who were diagnosed with knee osteoarthritis will be recruited for the study. Participants will be included in an exercise program tailored to their needs for 15 sessions. WOMAC, KOOS, LEFS scales will be used also knee range of motion will be assessed in the baseline, after treatments, in the 4th and 6th months.

Condition or Disease Intervention/Treatment Phase
  • Other: Exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Estimation of The Minimal Clinically Important Difference (MCID) for Commonly Used Outcome Measures in Patients With Knee Osteoarthritis
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Exercise

All patients will receive an exercise rehabilitation program tailored to their needs.

Other: Exercise
All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.

Outcome Measures

Primary Outcome Measures

  1. WOMAC [Baseline, after 15 session and 4 months follow up]

    Western Ontario and McMaster Universities Osteoarthritis Index

  2. KOOS [Baseline, after 15 session and 4 months follow up]

    Knee Injury and Osteoarthritis Outcome Score

  3. LEFS [Baseline, after 15 session and 4 months follow up]

    Lower Extremity Functional Scale

  4. Knee Range of Motion [Baseline, after 15 session and 4 months follow up]

    Range of motion assessment with goniometer

Secondary Outcome Measures

  1. 30s sit to stand test [Baseline, after 15 session and 4 months follow up]

    For functional assessment, patient sit and stand for 30 seconds

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • To be diagnosed with knee OA according to the criteria of the American Society of Rheumatology (ACR) (Diagnosis of primary knee OA)

  • Stage 2 or 3 according to Kellgren Lawrence radiological staging criteria

  • Participants with age between 50 and 70 years old

  • Being able to walk without using an assistive device

  • Having a body mass index of less than 30 kg/m²

  • Pain severity is between 3 and 7 according to the Numerical Pain Rating Scale

Exclusion Criteria:
  • Patients who received physical therapy or intra-articular injections in the last 6 months

  • Receiving an indication for surgery

  • Have severe hearing, vision and speech impairment

  • Having serious systemic and cardiovascular diseases that interfere with exercise

  • Having a lower extremity deformity

  • Patients with acute inflammation of the knee

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istinye University Physiotherapy and Rehabilitation Application and Research Center Istanbul Turkey

Sponsors and Collaborators

  • Istanbul University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Derya Celik, Professor, Istanbul University
ClinicalTrials.gov Identifier:
NCT06034665
Other Study ID Numbers:
  • DR2022
First Posted:
Sep 13, 2023
Last Update Posted:
Sep 13, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Derya Celik, Professor, Istanbul University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2023